US Pharma MarketingAlso, Memorial Sloan Kettering Cancer Center's mathematical optimisation engine will be co-developed as part of an Australian AI cancer treatment workflow platform. ASX-listed diagnostics AI company BlinkLab has raised A$17.5 million ($12.6 million) through an oversubscribed placement to support regulatory and commercial work for its AI-powered diagnostic aid for autism. Based on a company disclosure, the proceeds will fund BlinkLab's pivotal trial of the BlinkLab Dx1 to secure the United States Food and Drug Administration's 510(k) clearance, as well as regulatory work to obtain CE marking and EU MDR compliance. A portion of the new funds will also go to…
BlinkLab bags $13M for autism diagnostic AI
ASX-listed diagnostics AI company BlinkLab has raised A$17.5 million ($12.6 million) through an oversubscribed placement to support regulatory and commercial work for its AI-powered diagnostic aid for autism.
Based on a company disclosure, the proceeds will fund BlinkLab's pivotal trial of the BlinkLab Dx1 to secure the United States Food and Drug Administration's 510(k) clearance, as well as regulatory work to obtain CE marking and EU MDR compliance.
Source: MobiHealthNews